Treatment with a novel phospholipid-based drug formulation prevents behavioural deficits induced by proteasome inibition: implications for Parkinson's disease.
- Suzanne Crotty (Speaker)
- Fitzgerald, P. (Speaker)
- Arkady Mandel (Speaker)
- Anthony E. Bolton (Speaker)
- Sullivan, A. (Speaker)
- Nolan, Y. (Speaker)
Activity: Talk or presentation › Invited talk